Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03831932 |
|---|---|
| Brief Title: | Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer |
| First Submitted : | February 5, 2019 |
| First Submitted that Met QC Criteria : | February 5, 2019 |
| First Posted : | February 6, 2019 |
| Last Update Submitted that Met QC Criteria : | May 11, 2024 |
| Last Update Posted : | May 14, 2024 |